CL2015002181A1 - Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. - Google Patents

Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.

Info

Publication number
CL2015002181A1
CL2015002181A1 CL2015002181A CL2015002181A CL2015002181A1 CL 2015002181 A1 CL2015002181 A1 CL 2015002181A1 CL 2015002181 A CL2015002181 A CL 2015002181A CL 2015002181 A CL2015002181 A CL 2015002181A CL 2015002181 A1 CL2015002181 A1 CL 2015002181A1
Authority
CL
Chile
Prior art keywords
laquinimod
multiple sclerosis
treatment
progressive forms
progressive
Prior art date
Application number
CL2015002181A
Other languages
English (en)
Spanish (es)
Inventor
Nora Tarcic
Dan Bar-Zohar
Liat Hayardeny
Sherki Yossi Gilgun
Tali Gorfine
Volker Knappertz
Ella Sorani
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2015002181A1 publication Critical patent/CL2015002181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
CL2015002181A 2013-02-15 2015-08-05 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. CL2015002181A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03

Publications (1)

Publication Number Publication Date
CL2015002181A1 true CL2015002181A1 (es) 2016-06-03

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002181A CL2015002181A1 (es) 2013-02-15 2015-08-05 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.

Country Status (18)

Country Link
US (2) US20140235670A1 (https=)
EP (1) EP2956137A4 (https=)
JP (1) JP2016510343A (https=)
KR (1) KR20150119227A (https=)
CN (1) CN105163737A (https=)
AU (1) AU2014216199A1 (https=)
BR (1) BR112015019564A2 (https=)
CA (1) CA2900503A1 (https=)
CL (1) CL2015002181A1 (https=)
EA (1) EA201591507A1 (https=)
HK (2) HK1218254A1 (https=)
IL (1) IL240014A0 (https=)
MX (1) MX2015010296A (https=)
PE (1) PE20151526A1 (https=)
SG (1) SG11201505818WA (https=)
TW (1) TW201442709A (https=)
UY (1) UY35328A (https=)
WO (1) WO2014127139A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN114699409A (zh) * 2014-10-16 2022-07-05 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US8138201B2 (en) * 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
US20110268699A1 (en) * 2008-12-11 2011-11-03 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療
AU2011338647A1 (en) * 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
AU2012286701A1 (en) * 2011-07-28 2014-03-06 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
BR112015007782A2 (pt) * 2012-10-12 2017-07-04 Teva Pharma laquinimod para reduzir danos talâmicos na esclerose múltipla
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Also Published As

Publication number Publication date
UY35328A (es) 2014-09-30
CN105163737A (zh) 2015-12-16
EA201591507A1 (ru) 2015-12-30
HK1218251A1 (zh) 2017-02-10
EP2956137A1 (en) 2015-12-23
CA2900503A1 (en) 2014-08-21
WO2014127139A1 (en) 2014-08-21
BR112015019564A2 (pt) 2017-07-18
SG11201505818WA (en) 2015-08-28
US20140235670A1 (en) 2014-08-21
HK1218254A1 (zh) 2017-02-10
TW201442709A (zh) 2014-11-16
IL240014A0 (en) 2015-09-24
KR20150119227A (ko) 2015-10-23
MX2015010296A (es) 2016-05-05
PE20151526A1 (es) 2015-11-20
AU2014216199A1 (en) 2015-09-03
US20180064702A1 (en) 2018-03-08
EP2956137A4 (en) 2016-08-03
JP2016510343A (ja) 2016-04-07

Similar Documents

Publication Publication Date Title
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
UY34720A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego
EP3177311C0 (en) COMBINATION OF MEDICINAL PRODUCTS CONTAINING CABOZANTINIB AND A PROTEASOME INHIBITOR FOR THE TREATMENT OF MULTIPLE MYELOMA
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
PT3228313T (pt) Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina
CL2015002666A1 (es) Formas de dosificación sólidas de antiemético de liberación prolongada
UY35823A (es) Profármacos de antagonista de nmda
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
EA201690446A1 (ru) Лечение множественной миеломы
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
MX2017012449A (es) Tratamiento del dolor.
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
BR112015019792A2 (pt) composição para tratamento de hemorróidas e método de preparação